Evidence map›Paper›PMID 27743313›Full record

ArticleJournal of inherited metabolic disease2017

Functional characterization of missense mutations in severe methylenetetrahydrofolate reductase deficiency using a human expression system.

Patricie Burda, Terttu Suormala, Dorothea Heuberger, Alexandra Schäfer, Brian Fowler, D Sean Froese, Matthias R Baumgartner

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of inherited metabolic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Shifting landscapes of human MTHFR missense-variant effects.American journal of human genetics · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Patricie BurdaDivision of Metabolism, University Children's Hospital, CH-8032, Zurich, Switzerland.
Terttu SuormalaDivision of Metabolism, University Children's Hospital, CH-8032, Zurich, Switzerland.
Dorothea HeubergerDivision of Metabolism, University Children's Hospital, CH-8032, Zurich, Switzerland.
Alexandra SchäferDivision of Metabolism, University Children's Hospital, CH-8032, Zurich, Switzerland.
Brian FowlerDivision of Metabolism, University Children's Hospital, CH-8032, Zurich, Switzerland.
D Sean FroeseDivision of Metabolism, University Children's Hospital, CH-8032, Zurich, Switzerland. sean.froese@kispi.uzh.ch.
Matthias R BaumgartnerDivision of Metabolism, University Children's Hospital, CH-8032, Zurich, Switzerland. matthias.baumgartner@kispi.uzh.ch.
University Children's Hospital Zurich · CHUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

5,10-Methylenetetrahydrofolate reductase (MTHFR) catalyzes the NADPH-dependent reduction of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate using FAD as the cofactor. Severe MTHFR deficiency is the most common inborn error of folate metabolism, resulting in hyperhomocysteinemia and homocystinuria. Approximately 70 missense mutations have been described that cause severe MTHFR deficiency, however, in most cases their mechanism of dysfunction remains unclear. Few studies have investigated mutational specific defects; most of these assessing only activity levels from a handful of mutations using heterologous expression. Here, we report the in vitro expression of 22 severe MTHFR missense mutations and two known single nucleotide polymorphisms (p.Ala222Val, p.Thr653Met) in human fibroblasts. Significant reduction of MTHFR activity (<20 % of wild-type) was observed for five mutant proteins that also had highly reduced protein levels on Western blot analysis. The remaining mutations produced a spectrum of enzyme activity levels ranging from 22-122 % of wild-type, while the SNPs retained wild-type-like activity levels. We found increased thermolability for p.Ala222Val and seven disease-causing mutations all located in the catalytic domain, three of which also showed FAD responsiveness in vitro. By contrast, six regulatory domain mutations and two mutations clustering around the linker region showed increased thermostability compared to wild-type protein. Finally, we confirmed decreased affinity for NADPH in individual mutant enzymes, a result previously described in primary patient fibroblasts. Our expression study allows determination of significance of missense mutations in causing deleterious loss of MTHFR protein and activity, and is valuable in detection of aberrant kinetic parameters, but should not replace investigations in native material.

Indexed as

Amino Acid Metabolism, Inborn ErrorsCatalytic DomainFibroblastsGenotypeHomocystinuriaHumansHyperhomocysteinemiaKineticsMethylenetetrahydrofolate Reductase (NADPH2)Muscle SpasticityMutant ProteinsMutation, MissenseNADPPolymorphism, Single NucleotidePsychotic DisordersTetrahydrofolates5,10-methylenetetrahydrofolic acid5-methyltetrahydrofolateMethylenetetrahydrofolate Reductase (NADPH2)Mutant ProteinsNADPTetrahydrofolates

Identifiers

PMID27743313
OpenAlexW2531329651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.